Business
Senior Management Update
Senior Management Update.
About this update from Physiomics Plc
[{"type":"text","content":"\n\n4 September 2023\n \nPhysiomics plc\n(\"Physiomics\" or \"the Company\")\n \nSenior Management Update\n \nPhysiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce the hiring of a new member of its senior management team. Effective today, Dr Peter Sargent will be joining the Company as Chief Operating Officer (\"COO\").\nPrior to joining us, Dr Sargent held a senior management role at global consultancy business Syneos Health Inc (NASDAQ: SYNH), leading large teams of professionals and servicing a variety of clients in the biopharmaceuticals space. Among his earlier roles, Dr Sargent has also been Head of Business Development for the UK's National Institute for Health and Care Research (NIHR), leading a team supporting global life science businesses access to funding and research infrastructure in the UK.\nThe COO role will help to formulate the Company's overall business strategy and play a pivotal role in driving its execution. The initial focus will be to strengthen the operational performance of the Company and in particular drive the key priorities announced during the Company's recent placing, namely:\n· further expansion and diversification of its client base;\n· expansion of its consulting business into the adjacent area of pharmaceutical biostatistics services; and\n· exploration of opportunities around its personalised oncology software offering.\n \nDr Sargent will join as a key member of the Company's senior leadership team (but not as a board director) and will report directly to Dr Jim Millen. The hiring of Dr Sargent forms part of a strategy to revert to a more traditional board structure where the roles of Executive Chairman and CEO are separated. \n \nExecutive Chairman & CEO, Dr Jim Millen, commented:\n\"I am delighted that Physiomics has been able to attract a candidate of the calibre of Dr Peter Sargent, who joins us with significant experience of building service businesses in the biopharmaceutical sector. Peter will work closely with myself and my senior management team to set and drive forwards the Company's key business priorities and I look forward to...